Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial
Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …
heart failure with reduced ejection fraction, but additional information is needed about …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status-Results from the EMPEROR-Reduced Trial
SD Anker, J Butler, G Filippatos, MS Khan, N Marx… - Circulation, 2020 - hal.univ-lorraine.fr
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in
patients with heart failure with reduced ejection fraction, but additional information is needed …
patients with heart failure with reduced ejection fraction, but additional information is needed …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced …
SD Anker, J Butler, G Filippatos, MS Khan, N Marx… - Circulation, 2020 - europepmc.org
Background Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …
heart failure with reduced ejection fraction, but additional information is needed about …
[PDF][PDF] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
SD Anker, G Filippatos, MD Khan, N Marx, CSP Lam… - Circulation, 2021 - academia.edu
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients
with heart failure with reduced ejection fraction, but additional information is needed about …
with heart failure with reduced ejection fraction, but additional information is needed about …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
SD Anker, G Filippatos, MD Khan, N Marx, CSP Lam… - Circulation, 2021 - Am Heart Assoc
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients
with heart failure with reduced ejection fraction, but additional information is needed about …
with heart failure with reduced ejection fraction, but additional information is needed about …
[HTML][HTML] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR …
SD Anker, J Butler, G Filippatos, MS Khan, N Marx… - Circulation, 2021 - ncbi.nlm.nih.gov
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients
with heart failure with reduced ejection fraction, but additional information is needed about …
with heart failure with reduced ejection fraction, but additional information is needed about …
[PDF][PDF] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR …
SD ANKER, J BUTLER, G FILIPPATOS… - …, 2021 - observatorio.fm.usp.br
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients
with heart failure with reduced ejection fraction, but additional information is needed about …
with heart failure with reduced ejection fraction, but additional information is needed about …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
SD Anker, J Butler, G Filippatos, MS Khan, N Marx… - Circulation, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Sodium-glucose cotransporter
2 inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but …
2 inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status-Results from the EMPEROR-Reduced Trial
SD Anker, J Butler, G Filippatos, MS Khan, N Marx… - Circulation, 2020 - hal.science
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in
patients with heart failure with reduced ejection fraction, but additional information is needed …
patients with heart failure with reduced ejection fraction, but additional information is needed …
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced …
SD Anker, J Butler, G Filippatos, MS Khan… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …
heart failure with reduced ejection fraction, but additional information is needed about …